Clinical subtypes and genetic heterogeneity: of lumping and splitting in Parkinson disease

被引:50
|
作者
von Coelln, Rainer [1 ]
Shulman, Lisa M. [1 ]
机构
[1] Univ Maryland, Sch Med, Dept Neurol, 110 S Paca St, Baltimore, MD 21201 USA
关键词
akinetic-rigid; heterogeneity; Parkinson disease; postural instability/gait difficulty; subtypes; tremor-dominant; GENOME-WIDE ASSOCIATION; ALPHA-SYNUCLEIN; LRRK2; G2019S; DIAGNOSTIC-CRITERIA; LEWY BODY; RISK; CLASSIFICATION; GAIT; AGE; NEUROPATHOLOGY;
D O I
10.1097/WCO.0000000000000384
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose of review Recent studies on clinical, genetic and pathological heterogeneity of Parkinson disease have renewed the old debate whether we should think of Parkinson disease as one disease with variations, or as a group of independent diseases that happen to present with similar phenotypes. Here, we provide an overview of where the debate is coming from, and how recent findings in clinical subtyping, genetics and clinicopathological correlation have shaped this controversy over the last few years. Recent findings New and innovative clinical diagnostic criteria for Parkinson disease have been proposed and await validation. Studies using functional imaging or wearable biosensors, as well as biomarker studies, provide new support for the validity of the traditional clinical subtypes of Parkinson disease (tremor-dominant versus akinetic-rigid or postural instability/gait difficulty). A recent cluster analysis (as unbiased data-driven approach to subtyping) included a wide spectrum of nonmotor variables, and showed correlation of the proposed subtypes with disease progression in a longitudinal analysis. New genetic factors contributing to Parkinson disease susceptibility continue to be identified, including rare mutations causing monogenetic disease, common variants with small effect size and risk factors (like mutations in the gene for glucocerebrosidase) that fall in between the two other categories. Recent studies show some limited correlation between genetic factors and clinical heterogeneity. Despite some variations in patterns of pathology, Lewy bodies are still the hallmark of Parkinson disease, including the vast majority of genetic subgroups. Summary Evidence of clinical, genetic and pathological heterogeneity of Parkinson disease continues to emerge, but clearly defined subtypes that hold up in more than one of these domains remain elusive. For research to identify such subtypes, splitting is likely the way forward; until then, for clinical practice, lumping remains the more pragmatic approach.
引用
收藏
页码:727 / 734
页数:8
相关论文
共 50 条
  • [21] Exploring the Genetic Heterogeneity of Alzheimer's Disease: Evidence for Genetic Subtypes
    Elman, Jeremy A.
    Schork, Nicholas J.
    Rangan, Aaditya V.
    JOURNAL OF ALZHEIMERS DISEASE, 2024, 100 (04) : 1209 - 1226
  • [22] Subthalamic Physiology in Genetic Subtypes of Parkinson's Disease
    Pal, Gian D.
    David, Fabian J.
    Shils, Jay L.
    Munoz, Miranda J.
    Afshari, Mitra
    Sani, Sepehr
    Metman, Leo Verhagen
    Corcos, Daniel M.
    MOVEMENT DISORDERS, 2023, 38 (06) : 1113 - 1114
  • [23] Parkinson's disease in Ireland: Clinical presentation and genetic heterogeneity in patients with parkin mutations
    Wiley, J
    Lynch, T
    Lincoln, S
    Skipper, L
    Hulihan, M
    Gosal, D
    Bisceglio, G
    Kachergus, J
    Hardy, J
    Farrer, MJ
    MOVEMENT DISORDERS, 2004, 19 (06) : 677 - 681
  • [24] Parkinson disease clinical subtypes: key features & clinical milestones
    Campbell, Meghan C.
    Myers, Peter S.
    Weigand, Alexandra J.
    Foster, Erin R.
    Cairns, Nigel J.
    Jackson, Joshua J.
    Lessov-Schlaggar, Christina N.
    Perlmutter, Joel S.
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2020, 7 (08): : 1272 - 1283
  • [25] Evidence for genetic heterogeneity between clinical subtypes of bipolar disorder
    Charney, A. W.
    Ruderfer, D. M.
    Stahl, E. A.
    Moran, J. L.
    Chambert, K.
    Belliveau, R. A.
    Forty, L.
    Gordon-Smith, K.
    Di Florio, A.
    Lee, P. H.
    Bromet, E. J.
    Buckley, P. F.
    Escamilla, M. A.
    Fanous, A. H.
    Fochtmann, L. J.
    Lehrer, D. S.
    Malaspina, D.
    Marder, S. R.
    Morley, C. P.
    Nicolini, H.
    Perkins, D. O.
    Rakofsky, J. J.
    Rapaport, M. H.
    Medeiros, H.
    Sobell, J. L.
    Green, E. K.
    Backlund, L.
    Bergen, S. E.
    Jureus, A.
    Schalling, M.
    Lichtenstein, P.
    Roussos, P.
    Knowles, J. A.
    Jones, I.
    Jones, L. A.
    Hultman, C. M.
    Perlis, R. H.
    Purcell, S. M.
    McCarroll, S. A.
    Pato, C. N.
    Pato, M. T.
    Craddock, N.
    Landen, M.
    Smoller, J. W.
    Sklar, P.
    TRANSLATIONAL PSYCHIATRY, 2017, 7 : e993 - e993
  • [26] Evidence for genetic heterogeneity between clinical subtypes of bipolar disorder
    A W Charney
    D M Ruderfer
    E A Stahl
    J L Moran
    K Chambert
    R A Belliveau
    L Forty
    K Gordon-Smith
    A Di Florio
    P H Lee
    E J Bromet
    P F Buckley
    M A Escamilla
    A H Fanous
    L J Fochtmann
    D S Lehrer
    D Malaspina
    S R Marder
    C P Morley
    H Nicolini
    D O Perkins
    J J Rakofsky
    M H Rapaport
    H Medeiros
    J L Sobell
    E K Green
    L Backlund
    S E Bergen
    A Juréus
    M Schalling
    P Lichtenstein
    P Roussos
    J A Knowles
    I Jones
    L A Jones
    C M Hultman
    R H Perlis
    S M Purcell
    S A McCarroll
    C N Pato
    M T Pato
    N Craddock
    M Landén
    J W Smoller
    P Sklar
    Translational Psychiatry, 2017, 7 : e993 - e993
  • [27] Clinical and Biochemical Heterogeneity of Parkinson’s Disease
    Khadzieva K.I.
    Chernikova I.V.
    Milyutina N.P.
    Plotnikov A.A.
    Neuroscience and Behavioral Physiology, 2021, 51 (8) : 1073 - 1078
  • [28] Identifying genetic targets in clinical subtypes of Parkinson's disease for optimizing pharmacological treatment strategies
    Kong, Dewen
    Li, Cao
    Ma, Lingyan
    Du, Lida
    Jiang, Nan
    Zhao, Xiaoyue
    Zhang, Sen
    Zhao, Zhigang
    Fang, Lianhua
    Du, Guanhua
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [29] LUMPING AND SPLITTING OF THE AFFECTIVE SYNDROMES - CLINICAL AND BIOCHEMICAL ATTEMPTS
    AGREN, H
    PSYCHOPHARMACOLOGY, 1991, 103 (04) : B6 - B6
  • [30] Renal Cancer Subtypes: Should We Be Lumping or Splitting for Therapeutic Decision Making?
    Haake, Scott M.
    Rathmell, W. Kimryn
    CANCER, 2017, 123 (02) : 200 - 209